Compare Enveric Biosciences Inc (ENVB) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs KKR & Co Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while KKR & Co Inc trades at $111.14 (market cap $93.20B). The key difference: KKR & Co Inc is far larger — about 15032.3× Enveric Biosciences Inc's market cap, and KKR & Co Inc pays a 0.75% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KKR | |
|---|---|---|
Market Cap | $6.20M | $93.20B |
Sector | Health | Financials |
52-Week High | $17.40 | $149.34 |
52-Week Low | $1.27 | $83.88 |
Enterprise Value | $1.30M | $15.76B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
KKR trades at $102.81, down 0.52% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.63 per share, beating estimates, and maintains robust analyst support with a consensus price target of $127.22. Recent news highlights active deal-making, including the acquisition of Integer Holdings and the closing of a $19.2 billion infrastructure fund, signaling growth momentum.
The outlook for KKR is positive, driven by earnings beats, strategic acquisitions, and strong institutional sentiment. Key risks include execution of large deals, market volatility, and interest rate sensitivity. The stock presents an opportunity for growth-oriented investors, supported by a high buy rating consensus and expanding asset management operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
